Rusnak S L
Ann Allergy. 1981 Nov;47(5 Pt 1):320-4.
Twenty patients with asthma controlled by oral inhalations of beclomethasone dipropionate (400 micrograms/day) were treated for concurrent rhinitis by the addition of flunisolide nasal solution (300 micrograms/day) and its placebo for three weeks each in a randomized, double-blind, crossover trial. Flunisolide produced a statistically significant benefit for each symptom parameter: sneezing (p = 0.013), runny nose (p = 0.027), stuffy nose (p = 0.005 and over-all severity (p = 0.005). More concomitant rhinitis medication was used during placebo treatment (p = 0.069). Seventy percent of the patients had "total" or "substantial" control of nasal symptoms with flunisolide vs. 45% with placebo (p less than 0.01). Eighty percent felt that flunisolide was either the only active drug or the more active (p less than 0.01). Three morning plasma cortisol determinations during the last week of each treatment period showed no drug-related effect. No nasal cultures were positive for Candida; the incidence of positive pharyngeal; cultures did not vary significantly. Adverse reactions consisted primarily of nasal burning and stinging; none was serious. In this group of twenty patients using inhalations of beclomethasone dipropionate for asthma, accompanying perennial rhinitis was substantially controlled by 300 micrograms of flunisolide nasal solution per day without significant additive effect on plasma cortisol levels or the incidence of overgrowth of Candida.
在一项随机、双盲、交叉试验中，20名通过吸入二丙酸倍氯米松（400微克/天）控制哮喘的患者，分别接受了添加氟尼缩松鼻用溶液（300微克/天）及其安慰剂治疗，各为期三周，以治疗并发的鼻炎。氟尼缩松在每个症状参数上均产生了具有统计学意义的益处：打喷嚏（p = 0.013）、流鼻涕（p = 0.027）、鼻塞（p = 0.005）以及总体严重程度（p = 0.005）。在安慰剂治疗期间使用了更多的鼻炎伴随用药（p = 0.069）。70%的患者使用氟尼缩松时对鼻部症状有“完全”或“显著”控制，而使用安慰剂时为45%（p小于0.01）。80%的患者认为氟尼缩松要么是唯一的有效药物，要么是更有效的药物（p小于0.01）。在每个治疗期的最后一周进行的三次晨间血浆皮质醇测定显示无药物相关影响。鼻培养物中念珠菌均为阴性；咽培养物阳性发生率无显著差异。不良反应主要为鼻部烧灼感和刺痛感；均不严重。在这20名使用二丙酸倍氯米松吸入剂治疗哮喘的患者中，每天300微克的氟尼缩松鼻用溶液可有效控制伴随的常年性鼻炎，且对血浆皮质醇水平或念珠菌过度生长的发生率无显著附加影响。
